<DOC>
	<DOCNO>NCT00004042</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody F19 treat patient advanced metastatic cancer .</brief_summary>
	<brief_title>Monoclonal Antibody F19 Treating Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Identify toxicity associate increase dos monoclonal antibody F19 ( BIBH-1 ) administer weekly intravenous infusion patient unresectable , advanced metastatic fibroblast activation protein-positive colorectal cancer . II . Determine dose limit toxicity maximum tolerate dose drug patient . III . Measure induction titer human anti-human antibody BIBH-1 correlate immunologic-related clinical effect . IV . Determine pharmacokinetics , biodistribution , image characteristic increase intravenous dos drug . V. Document tumor response patient population . OUTLINE : This dose escalation , open label , multicenter study . Patients receive monoclonal antibody F19 ( BIBH-1 ) IV 60 minute weekly 12 week . The first , fifth , ninth treatment combine iodine I 131 . Patients stable respond disease may continue treatment 12 month . The dose BIBH-1 escalate cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow 1 month . PROJECTED ACCRUAL : A maximum 24 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable , advanced and/or metastatic disease : Colorectal cancer Measurable evaluable disease Epidemiologically proven fibroblast activation protein positive Failed refuse conventional treatment , unlikely derive significant benefit conventional treatment No active CNS metastases No new progressive lesion CT scan , 3 month since treatment ( i.e. , surgery radiotherapy ) brain metastasis , and/or receive mitomycin Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : At least 4 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : ALT/AST great 3 time upper limit normal Bilirubin le 2 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No serious illness No active infection require antibiotic No bleed disorder No disease may potentially interfere obtain accurate study result PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No prior murine , chimeric humanize antibody and/or antibody fragment Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : No concurrent systemic corticosteroid ( except acute management allergictype event ) No concurrent immunosuppressive agent Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Recovered surgery Other : At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>